Individual data collection forms, designed as part
of the cohort
study, documented duration
of labour, mode
of delivery, some forms
of pain relief, active management
of the
third stage of labour, whether an episiotomy was performed, clinical complications, length
of stay for both mother and baby by type
of ward and level
of care, and transfers by duration and mode.
Table 1: Selection, Design & Construction
of HSV - based Oncolytic Viruses Table 2: Selection, Design & Construction
of Adenovirus - based Oncolytic Viruses Table 3: Selection, Design & Construction
of Vaccinia Virus - based Oncolytic Viruses Table 4: Selection, Design & Construction
of Vesicular Stomatitis Virus - based Oncolytic Viruses Table 5: Selection, Design & Construction
of Newcastle Disease Virus - based Oncolytic Viruses Table 6: Selection, Design & Construction
of Various Virus - based Oncolytic Viruses Table 7: Current Company - Sponsored Clinical Trials
of T - Vec Table 8: Clinical Trials
of ColoAd1 Table 9: Clinical Trials with JX - 594 Table 10: Clinical Trials with GL - ONC1 Table 11: Clinical Trials
of CAVATAK (CVA21) Table 12: Clinical Trials with MV - NIS Table 13: Overview
of Oncolytic Viruses by Development Phase & Virus Family Table 14: Profile
of Approved and Marketed Oncolytic Viruses Table 15: Pivotal
Study Design
of Oncolytic Viruses in Late
Stage Development Based on Previous Clinical Results Table 16: Approved Indications
of Immune Checkpoint Inhibitors Table 17: Active Clinical
Studies of Oncolytic Viruses in Combination with Immune Checkpoint Inhibitors (ICI) Table 18: Planned Clinical
Studies of Oncolytic Viruses in Combination with Immune Checkpoint Inhibitors (ICI) Table 19: Active or Planned Clinical
Studies of Oncolytic Viruses in Combination with Other Anti-Cancer Therapeutics Table 20: Pattern
of Transgenes in Oncolytic Viruses in Relation to Development Phase Tables 21a and 21b: Indications and Frquency and Way
of Administration
of Oncolytic Viruses in Active and / or Positive Completed Clinical
Studies Table 22: Small and Medium Pharma & Biotech as Partner for Regional Co-Development
of Oncolytic Viruses Table 23: Immuno - Oncology Portfolio
of Major Pharma & Biotech with Interest in Oncolytic Viruses Table 24: Interests
of Major Pharma & Biotech in Oncolytic Viruses Table 25: First Generation Oncology Virus Companies and their Sources
of Technology Table 26: Second Generation Oncology Virus Companies and their Sources
of Technology Table 27:
Third Generation Oncology Virus Companies and their Sources
of Technology Table 28: Fourth Generation Oncology Virus Companies and their Sources
of Technology Table 29: Grants, Credits & Donations Table 30: Financing by Venture Capital, Private Equity and Other Private Placements Table 31: Collaboration & Licensing Agreements Table 32: Companies Listed on Stock Exchange & Offerings Table 33: Mergers & Acquisitions
A generous hint
of his direction could be seen in the 2012 Biennial (then hailed by New York Times critic Roberta Smith as «one
of the best Whitney Biennials in recent memory»), which included such unforgettable moments as Werner Herzog's presentation
of drawings by Hercules Segers intermixed with filmed performances by the Dutch avant - garde cellist and composer Ernst Reijseger; Dawn Kasper's performative residency in a ramshackle studio
of her own creation on the museum's
third floor; and the transformation
of the entire fourth floor into a long
stage for dance, most memorably Michelson's highly concentrated, multipart «Devotion
Study # 1 — The American Dancer.»